CompletedPhase 2NCT03231306
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
Studying Neurofibromatosis type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alabama at Birmingham
- Principal Investigator
- Bruce Korf, MD, PhD, MSW, LICSWUniversity of Alabama at Birmingham
- Intervention
- Binimetinib(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 2017 – 2024
Study locations (22)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- University of California at Los Angeles, Los Angeles, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- University of California, San Diego - Rady Children's Hospital, San Diego, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- National Institute of Health - National Cancer Institute, Bethesda, Maryland, United States
- Boston Children's Hospital / Dana Farber Cancer Institute / Massachusetts General Hospital, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- New York University Medical Center, New York, New York, United States
- +7 more locations on ClinicalTrials.gov
Collaborators
Array BioPharma · Pacific Pediatric Neuro-Oncology Consortium
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03231306 on ClinicalTrials.govOther trials for Neurofibromatosis type 1
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06507748A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Johns Hopkins University
- RECRUITINGNANCT07221331Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)AstraZeneca
- RECRUITINGNANCT07088991Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaAstraZeneca
- RECRUITINGPHASE1NCT06961565PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasPasithea Therapeutics Corp.
- RECRUITINGNANCT06880991Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative StudyNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06541847A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1Healx Limited
- RECRUITINGNANCT06222203Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)National Cancer Institute (NCI)